Most (54%) respondents indicated that they believe the FDA made a mistake when it approved the controversial Alzheimer’s drug in June 2021.
The dust still hasn’t settled on the FDA’s controversial decision last year to approve Biogen’s Alzheimer’s drug, Aduhelm (aducanumab). Last week CMS announced that it is proposing to cover the drug only if the patient is enrolled in an approved clinical trial, a move that seems to reflect concern the FDA’s OK was based on shaky evidence. Biogen fired off a press release said if the Jan. 11 coverage decision doesn’t change, nearly all Medicare beneficiaries will be denied access to its drug. Biogen had already tried to blunt some of the criticism of its anti-amyloid drug by slashing its price in half, from $56,000 a year, on average, to $28,200.
Related: 5 Things You Should Know About the Aduhelm Price Cut
Most of the respondents to our annual State of the Industry are in the skeptical/critical camp when it comes to Aduhelm: 54% indicated that they believed it was a mistake for the FDA to approve the drug. The survey had 100 respondents, although not every respondent answered all the questions.
Aduhelm was approved on the FDA’s accelerated pathway, which, among other things, means a drug will be judged by the agency on its effects on surrogate markers for management or control of a disease rather than on manifestations of the disease itself. The solid majority believes the Aduhelm approval was a misstep but an even larger majority (74%) of the respondents indicated that they didn’t think the FDA has approved too many drugs through the accelerated approval process.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More